This article was downloaded by: [University of Arizona] On: 26 December 2012, At: 06:32 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/Incn20

# SYNTHESIS AND IN VITRO ACTIVITY OF D- AND L-ENANTIOMERS OF 5-(TRIFLUOROMETHYL)URACIL NUCLEOSIDE DERIVATIVES

Raul Salvetti<sup>a</sup>, Massimo Pregnolato<sup>b</sup>, Annalisa Verri, Federico Focher, Silvio Spadari, Arnaud Marchand<sup>c</sup>, Christophe Mathé<sup>c</sup> & Gilles Gosselin<sup>c</sup>

<sup>a</sup> Università di Pavia, V. Taramelli 12, Pavia, 27100, Italy

<sup>b</sup> Università di Pavia, V. Taramelli 12, Pavia, 27100, Italy

<sup>c</sup> UMR 5625 CNRS, Université Montpellier II, Montpellier, Cedex 5, 34095, France Version of record first published: 07 Feb 2007.

To cite this article: Raul Salvetti, Massimo Pregnolato, Annalisa Verri, Federico Focher, Silvio Spadari, Arnaud Marchand, Christophe Mathé & Gilles Gosselin (2001): SYNTHESIS AND IN VITRO ACTIVITY OF D- AND L-ENANTIOMERS OF 5-(TRIFLUOROMETHYL)URACIL NUCLEOSIDE DERIVATIVES, Nucleosides, Nucleotides and Nucleic Acids, 20:4-7, 1123-1125

To link to this article: <u>http://dx.doi.org/10.1081/NCN-100002502</u>

### PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <u>http://www.tandfonline.com/page/terms-and-conditions</u>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

#### NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4-7), 1123-1125 (2001)

### SYNTHESIS AND *IN VITRO* ACTIVITY OF D- AND L-ENANTIOMERS OF 5-(TRIFLUOROMETHYL)URACIL NUCLEOSIDE DERIVATIVES

Raul Salvetti,<sup>1</sup> Massimo Pregnolato,<sup>1,\*</sup> Annalisa Verri,<sup>2</sup> Federico Focher,<sup>2</sup> Silvio Spadari,<sup>2</sup> Arnaud Marchand,<sup>3</sup> Christophe Mathé,<sup>3</sup> and Gilles Gosselin<sup>3</sup>

 <sup>1</sup>Università di Pavia, V. Taramelli 12, 27100 Pavia, Italy
<sup>2</sup>CNR, IGBE, via Abbiategrasso 207, 27100, Pavia, Italy
<sup>3</sup>UMR 5625 CNRS-Université Montpellier II, 34095 Montpellier Cedex 5, France

#### ABSTRACT

Recently,  $\beta$ -L-nucleoside analogues have emerged as a new class of sugar modified nucleosides with potential antiviral and/or antitumoral activity. As a part of our ongoing research on this topic, we decided to synthesize 5-CF<sub>3</sub>- $\beta$ -L-dUrd (7), the hitherto unknown L-enantiomer of Trifluridine, an antiherpetic drug approved by FDA but only used in topical applications due to concomitant cytotoxicity. 5-CF<sub>3</sub>- $\beta$ -L-dUrd (7) as well as some other related L-nucleoside derivatives were stereospecifically prepared and tested *in vitro* against viral (HSV-1 and HSV-2) and human thymidine kinases (TK).

Trifluridine (Viroptic<sup>TM</sup>) is an antiherpetic drug approved by the FDA in 1980 for the clinical treatment of primary keratoconjunctivitis and epithelial keratitis (1). It is monophosphorylated by both cellular and HSV thymidine kinases, and upon further phosphorylation by cellular nucleotide kinases, it inhibits viral DNA replication by incorporation of its triphosphate form into DNA. On the other hand, interactions of Trifluridine and its phosphorylated metabolites with cellular enzymes, including human thymidine kinase, thymidylate synthase, and DNA

<sup>\*</sup>Corresponding author.

ORDER		REPRINTS
-------	--	----------

#### SALVETTI ET AL.

polymerases are responsible for cellular toxicity. In order to design compounds with reduced cytotoxic effects, we have carried out the synthesis of  $5\text{-}CF_3-\beta\text{-}L\text{-}dUrd$  (7), the L-enantiomer of Trifluridine, as well as some other L-nucleoside derivatives modified at the 2' and 3' positions of the sugar moiety. Condensation of 1,2-di-*O*-acetyl-3,5-di-*O*-benzoyl-L-xylofuranose (2) (1) with commercially available 5-(trifluoromethyl)uracil under Vorbrüggen conditions gave 1-(2-*O*-acetyl-3,5-di-*O*-benzoyl- $\beta$ -L-xylo-furanosyl)-5-(trifluoromethyl)uracil (2) which was fully deacylated to give  $\beta$ -L-xylofuranosyl-5-(trifluoromethyl)uracil 8 (Scheme 1). On the other hand, regioselective 2'-*O*-deacylation of compound 2 afforded 1-(3,5-di-*O*-benzoyl- $\beta$ -L-xylo-furanosyl)-5-(trifluoromethyl)uracil (3), which was converted *via* a radical reductive process (3) to compound 4, and upon deprotection, gave 1-(2-deoxy- $\beta$ -L-*threo*-pentofuranosyl)-5-(trifluoromethyl)uracil (5). Selective 5'-*O*-benzoylation of compound 5 provided the key-intermediate 6.

From 6, inversion of configuration at C-3' *via* a Mitsunobu reaction (4), and subsequent debenzoylation with methanolic ammonia gave the target molecule



Scheme 1. Reagents and conditions: (a) silylated 5-CF<sub>3</sub>-uracil/TMSOTf/dichloroethane, r.t.; (b)  $H_2N-NH_2.H_2O/AcOH/pyridine, r.t.;$  (c)  $NH_3/MeOH, r.t.;$  (d)  $DMAP/PhO(C=S)Cl/CH_3CN, r.t.;$  then,  $(Me_3Si)_3SiH/AIBN/dioxane, reflux;$  (e)  $BzCl/pyridine, 0^{\circ}C;$  (f)  $DEAD/benzoic acid/THF, 0^{\circ}C;$  (g) MsCl/TBAF/THF, r.t.; then, MeONa/MeOH, r.t.



Copyright © Marcel Dekker, Inc. All rights reserved

ORDER		REPRINTS
-------	--	----------

#### 5-(TRIFLUOROMETHYL)URACIL NUCLEOSIDE DERIVATIVES

1000 1.								
	ни СF3 of N Но ОН 5	HN CF3 HO ON OH D-counterpart		HN CF3 HO ON OH Trifluridine		HO HO OH D-counterpart		
HSV-1TK IC <sub>50</sub> (μM)	45	24	0.5	0.25	13	32		
HSV-2TK IC <sub>50</sub> (μM)	119	56	14.5	2	115	164		

Table 1.

5-CF<sub>3</sub>- $\beta$ -L-dUrd (7). Starting from the same key-intermediate 6, other modifications on 2' and 3' positions provided the corresponding 2',3'-dideoxynucleoside 9 and the 2',3'-unsaturated derivative 10.

The potential inhibitory effects of compounds **5**, **7** and **8** *versus* their Dnucleoside counterparts toward the thymidine kinases (5) of HSV-1 and HSV-2 have been evaluated. The IC<sub>50</sub> values are reported in Table 1. All the nucleosides (D and L) show higher affinity for HSV-1 TK with respect to HSV-2 TK. Furthermore, 5-CF<sub>3</sub>- $\beta$ -L-dUrd (7) and commercially available Trifluridine show the best inhibitory properties toward both viral enzymes. Regarding HSV-2 TK, Trifluridine shows an IC<sub>50</sub> value of 2  $\mu$ M while 5-CF<sub>3</sub>- $\beta$ -L-dUrd shows a higher value (14.5  $\mu$ M). On the other hand, against HSV-1 TK 5-CF<sub>3</sub>- $\beta$ -L-dUrd (7) has an IC<sub>50</sub> value of 0.5  $\mu$ M which is comparable to the IC<sub>50</sub> value (0.25  $\mu$ M) found for Trifluridine. This last result seems promising in term of potential antiherpetic activity for 5-CF<sub>3</sub>- $\beta$ -L-dUrd (7).

In order to investigate the potential antiherpetic activity of 7 and to study its cellular effects of 5-CF<sub>3</sub>- $\beta$ -L-dUrd (7), we have evaluated its inhibition of cellular TK. Trifluridine shows an IC<sub>50</sub> value of 2  $\mu$ M while its L-enantiomer is not able to inhibit cellular TK up to a concentration of 200  $\mu$ M. This result appears very interesting in terms of a lack of cellular toxicity for 5-CF<sub>3</sub>- $\beta$ -L-dUrd (7). Based on these results, the antiherpetic evaluation of 5-CF<sub>3</sub>- $\beta$ -L-dUrd (7) in cell cultures is warranted, and work on this topic is currently in progress in our laboratories.

#### REFERENCES

- 1. Carmine, A.A.; Brogden, R.N.; Heel, R.C.; Speight, T.M.; Avery, G.S. *Drugs* **1982**, 23, 329–53.
- Gosselin, G.; Bergogne, M.-C.; Imbach, J.-L. J. Heterocycl. Chem. 1993, 30, 1229– 1233.
- 3. Barton, D.H.R.; McCombie, S.W. J. Chem. Soc. Perkin Trans 1 1975, 1574–1585.
- 4. Hughes, D.L. Org. Prep. Proced. Int. 1996, 28, 127–164.
- Spadari, S.; Maga, G.; Veni, A.; Focher, F. *Exp. Opin. Invest. Drugs* 1998, 7, 1285– 1300. Marcel Dekker, Inc.

1125



Copyright @ Marcel Dekker, Inc. All rights reserved

### **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the <u>U.S. Copyright Office</u> for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on <u>Fair Use in the Classroom</u>.

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our <u>Website</u> <u>User Agreement</u> for more details.

# **Order now!**

Reprints of this article can also be ordered at http://www.dekker.com/servlet/product/DOI/101081NCN100002502